Serotonergic Hallucinogens

  • Mireille M. Meyerhoefer


In a fundamental sense, perceptions define our world and our place within it. Mind altering compounds have been a source of fascination, recreation, and deification throughout human history. We now know that some of the oldest hallucinogens produce their effects through the serotonin system. In addition to the sense of enlightenment sought by casual users there is renewed interest in the potential use of these drugs therapeutically and as tools for studying the mind and mental illness. Serotonergic hallucinogens may hold particular promise in this regard because of the already established links between the serotonergic system and mental processes such as idiopathic psychosis, anxiety, depression, migraine headaches, transcendental states, drug abuse, stress disorders, and cognitive dysfunctions.


Hallucinogen Lysergic acid diethylamide Mescaline Ecstasy Serotonin Flashbacks Indolealkylamine hallucinogens Phenethylamine hallucinogens 


  1. 1.
    Abraham H (1982) A chronic impairment of colour vision in users of LSD. Br J Psychiatry 140:518–520PubMedCrossRefGoogle Scholar
  2. 2.
    Abraham H (1983) Visual phenomenology of the LSD flashbacks Arch Gen Psychiatry 40:884–889Google Scholar
  3. 3.
    Abraham H, Aldridge A (1993) Adverse consequences of lysergic acid diethylamide. Addiction 88:1327–1334PubMedCrossRefGoogle Scholar
  4. 4.
    Abraham H, Aldridge A, Gogia P (1996) The psychopharmacology of hallucinogens. Neuropsychopharmacology 14(4):285–298PubMedCrossRefGoogle Scholar
  5. 5.
    Abraham H, Andrew AM (1993) Adverse consequences of lysergic acid diethylamide. Addiction 88:1327–1334PubMedCrossRefGoogle Scholar
  6. 6.
    Abraham H, Mamen A (1996) LSD-like panic from risperidone in post-LSD visual disorder. J Clin Psychopharmacol 16:238–241PubMedCrossRefGoogle Scholar
  7. 7.
    Abraham H, Wolfe E (1988) Visual function in past users of LSD: psychophysical findings. J Abnorm Psychol 97:443–447PubMedCrossRefGoogle Scholar
  8. 8.
    Aghajanian G, Bing O (1964) Persistence of lysergic acid diethylamide in the plasma of human subjects. Clin Pharmacol Ther 5:611–614PubMedGoogle Scholar
  9. 9.
    Alarcon R, Dickinson W, Dohn H (1982) Flashback phenomena: clinical and diagnostic dilemmas. J Nerv Ment Dis 170(4):217–223PubMedCrossRefGoogle Scholar
  10. 10.
    Aldurra G, Crayton J (2001) Improvement of hallucinogen-induced persistent perception disorder by treatment with a combination of fluoxetine and olanzapine: case report. J Clin Psychopharmacol 21(3):343–344PubMedCrossRefGoogle Scholar
  11. 11.
    Anderson W, O’Malley J (1972) Trifluoperazine for the trailing phenomena. JAMA 220:1244–1245PubMedGoogle Scholar
  12. 12.
    Andreu V, Mas A, Bruguera M et al (1998) Ecstasy: a common cause of severe acute hepatotoxicity. J Hepatol 29:394–397PubMedCrossRefGoogle Scholar
  13. 13.
    Appel J, Freedman D (1968) Tolerance and cross-tolerance among psychotomimetic drugs. Psychopharmacologia 20:13(3):267–274CrossRefGoogle Scholar
  14. 14.
    Badaoui R, El Kettani C, Fikri M et al (2002) Spontaneous cervical and mediastinal air emphysema after Ecstasy abuse. Anesth Analg 95:1123PubMedGoogle Scholar
  15. 15.
    Barnes NM, Sharp T (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38(8):1083–1152PubMedCrossRefGoogle Scholar
  16. 16.
    Bengel D, Murphy D, Andrews A et al (1998) Altered brain serotonin homeostasis and locomotor insensitivity to 3, 4-methylenedioxymethamphetamine (‘Ecstasy’) in serotonin transporter-deficient mice. Mol Pharmacol 53:649–655PubMedGoogle Scholar
  17. 17.
    Blaho K, Merigian K, Winbery S et al (1997) Clinical pharmacology of lysergic acid diethylamide: case reports and review of the treatment of intoxication. Am J Ther 4:211–221PubMedCrossRefGoogle Scholar
  18. 18.
    Brodkin J, Malyala A, Nash JF (1993) Effect of acute monoamine depletion on 3,4-methylenedioxymethamphetamine-induced neurotoxicity. Pharmacol Biochem Behav 45:647–653PubMedCrossRefGoogle Scholar
  19. 19.
    Busch AK, Johnson WC (1950) LSD as an aid to psychotherapy. Dis Nerve Sys 11:241–243Google Scholar
  20. 20.
    Cami J, Farre M, Mas M et al (2002) Human pharmacology of 3,4-methylenedioxymethamphetamine (“ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol 20:455–466CrossRefGoogle Scholar
  21. 21.
    Caporael L (1976) Ergotism: the satan lossed in salem? Science 192:21–26PubMedCrossRefGoogle Scholar
  22. 22.
    Climko R, Roechrich H, Sweeney D et al (1987) Ecastacy [sic]: a review of MDMA and MDA. Int J Psychiatry Med 16:359–372CrossRefGoogle Scholar
  23. 23.
    Cohen M, Shiloh Y (1977/78) Genetic toxicology of lysergic acid diethylamide (LSD25). Mutat Res 47:183–209PubMedCrossRefGoogle Scholar
  24. 24.
    Cohen S (1984) The hallucinogen and the inhalants. Psychiatr Clin North Am 7:681–688PubMedGoogle Scholar
  25. 25.
    Colado M, Williams J, Green A (1995) The hyperthermic and neurotoxic effects of “Ecstasy” (MDMA) and 3,4 methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br J Pharmacol 115:1281–1289PubMedCrossRefGoogle Scholar
  26. 26.
    Cole J, Sumnall H (2003) Altered states: the clinical effects of Ecstasy. Pharmacol Ther 98:35–58PubMedCrossRefGoogle Scholar
  27. 27.
    Curan HV, Travill RA (1997) Mood and cognitive effects of 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week end ‘high’ followed by mid-week low. Addiction 92:821–831Google Scholar
  28. 28.
    Curry S, Rose M (1985) Intravenous mushroom poisoning. Ann Emerg Med 14:900–902PubMedCrossRefGoogle Scholar
  29. 29.
    De la Torre R, Farre M, Ortuno J (2000) Non-linear pharmacokinetics of MDMA (“ecstasy”) in humans. Br J Clin Pharmacol 49:104–109PubMedCrossRefGoogle Scholar
  30. 30.
    De la Torre R, Farre M, Roset PN et al (2000) Pharmacology of MDMA in humans. Ann NY Acad Sci 914:225–237PubMedCrossRefGoogle Scholar
  31. 31.
    De la Torre R, Farre M, Roset PN et al. (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism and disposition. Ther Drug Monit 23:137–144CrossRefGoogle Scholar
  32. 32.
    Diagnostic Statistical Manual IV (2000) American Psychiatric Association, Arlington, VAGoogle Scholar
  33. 33.
    DiSclafani A, Hall R, Garder E (1981) Drug-Induced psychosis: emergency diagnosis and management. Psychosomatics 22(10)845–855PubMedGoogle Scholar
  34. 34.
    Drug Enforcement Administration, Office of Diversion Control, Accessed on 01 Aug 2008
  35. 35.
    Ellis A, Wendon J, Portmann B et al (1996) Acute liver damage and ecstasy ingestion. Gut 38:454–458PubMedCrossRefGoogle Scholar
  36. 36.
    European Monitoring Centre for Drugs and Drug Addiction (2003) Annual report on the state of drugs problems in the European Union and Norway. EMCDDA, LisbonGoogle Scholar
  37. 37.
    Fidler H, Dhillon A, Gertner D (1996) Chronic ecstasy (3,4-methylenedioxymethamphetamine) abuse: a recurrent and unpredictable cause of severe acute hepatitis. J Hepatol 25:563–566PubMedCrossRefGoogle Scholar
  38. 38.
    Fink M, Simeon J, Haque W et al (1966) Prolonged adverse reactions to LSD in psychotic subjects. Arch Gen Psychiatry 15:450–454PubMedCrossRefGoogle Scholar
  39. 39.
    Fiorella D, Helsley S, Lorrain DS et al (1995) The role of the 5-HT2A and 5-HT2C receptors in the stimulus effects of hallucinogenic drugs. III: the mechanistic basis for supersensitivity to the LSD stimulus following serotonin depletion. Psychopharmacology 121(3):364–372PubMedCrossRefGoogle Scholar
  40. 40.
    Gaggott M, Heifets B, Jones R et al (2000) Chemical analysis of ecstasy pills. JAMA 284:2190CrossRefGoogle Scholar
  41. 41.
    Gahlinger P (2004) Club drugs: MDMA, gamma-hydroxybutyrate (GHB), rohypnol, and ketamine. Am Fam Physician 69(11):2619–2626PubMedGoogle Scholar
  42. 42.
    Garratt JC, Alreja M, Aghajanian GK (1993) LSD has high efficacy relative to serotonin in enhancing the cationic current in intracellular studies in rate facial motor neurons. Synapse 13:123–134PubMedCrossRefGoogle Scholar
  43. 43.
    Gillman P (2005) Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 95:434–441PubMedCrossRefGoogle Scholar
  44. 44.
    Gledhill J, Moore D, Bell D et al (1993) Subarachnoid haemorrhage associated with MDMA use. J Neurol Neurosurg Psychiatry 56:1036–1037PubMedCrossRefGoogle Scholar
  45. 45.
    Gore S (1999) Fatal uncertainty: death rate from use of ecstasy or heroin. Lancet 354:1265–1266PubMedCrossRefGoogle Scholar
  46. 46.
    Graeme K (2000) New drugs of abuse. Emerg Med Clin North Am 18:625–636PubMedCrossRefGoogle Scholar
  47. 47.
    Green A, Mechan A, Elliott J (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55:463–508PubMedCrossRefGoogle Scholar
  48. 47.
    Green A, Mechan A, Elliott J et al (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ‘Ecstasy’). Pharmacol Rev 55:463–508PubMedCrossRefGoogle Scholar
  49. 48.
    Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18:319–327PubMedCrossRefGoogle Scholar
  50. 49.
    Greiner T, Burch NR, Edelberg R (1958) Psychopathology and psychophysiology of minimal LSD-25 dosage; a preliminary dosage-response spectrum. Arch Neurol Psychiatry 79(2):208–210CrossRefGoogle Scholar
  51. 50.
    Griffiths R, Richards W, McCann U et al (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology 187(3):268–283PubMedCrossRefGoogle Scholar
  52. 51.
    Hall A, Henrey J (2006) Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anesth 96(6):678–685CrossRefGoogle Scholar
  53. 51.
    Hall A, Henrey J (2006) Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anesth 96(6):678–685CrossRefGoogle Scholar
  54. 51.
    Hall A, Henrey J (2006) Acute toxic effects of ‘Ecstasy’ (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 96(6):678–685PubMedCrossRefGoogle Scholar
  55. 52.
    Harries D, De Silva R (1992) Ecstasy and intracerebral haemorrhage. Scot Med J 37:150–152PubMedGoogle Scholar
  56. 53.
    Hartung T, Schofield E, Short A et al (2002) Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’) ingestion. Q J Med 95:431–437CrossRefGoogle Scholar
  57. 54.
    Henry J, Fallon J, Kicman A et al (1998) Low-dose MDMA (‘ecstasy’) induces vasopressin secretion. Lancet 351:1784PubMedCrossRefGoogle Scholar
  58. 55.
    Henry J (1992) Ecstasy and the dance of death. Br Med J 305:5–6CrossRefGoogle Scholar
  59. 56.
    Henry J, Jeffreys K, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxymethamphetamine (“ecstasy”). Lancet 340:384–387PubMedCrossRefGoogle Scholar
  60. 57.
    Hoch PH, Cattell JP, Pennes HH (1952) Effects of mescaline and lysergic acid (d-LSD-25). Am J Psychiatry 108(8):579–584PubMedGoogle Scholar
  61. 58.
    Hofmann A (1980) LSD—My problem child. McGraw-Hill, New YorkGoogle Scholar
  62. 59.
    Hollister L, Hartman A (1962) Mescaline, lysergic acid diethylamide and psilocybin: comparison of clinical syndromes, effects on color perception and biochemical measures. Compr Psychiatry 3:235–241PubMedCrossRefGoogle Scholar
  63. 60.
    Horowitz MJ (1969) Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry 126:565–569PubMedGoogle Scholar
  64. 61.
    Hoyer D, Hannon JP, Marten GR (2002) Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 71:533–554PubMedCrossRefGoogle Scholar
  65. 62.
    Hughes J, McCabe M, Evans R (1993) Intracranial haemorrhage associated with ingestion of ‘Ecstasy.’ Arch Emerg Surg 10:372–374Google Scholar
  66. 63.
    Inman D, Green D (2003) The agony and the ecstasy: acute urinary retention after MDMA abuse. BJU Int 91:123PubMedCrossRefGoogle Scholar
  67. 64.
    Isbell H, Wolbach A, Wikler A et al (1961) Cross tolerance between LSD and psilocybin. Psychopharmacologia 2:147–159PubMedCrossRefGoogle Scholar
  68. 65.
    Johnson M, Hoffman A, Nichols D (1986) Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices. Eur J Pharmacol 132:269–276PubMedCrossRefGoogle Scholar
  69. 66.
    Johnston L, O’Malley P, Bachman J et al (2008) Monitoring the future national results on adolescent drug use: overview of key findings, 2007, NIH Publication No. 08–6418. National Institute on Drug Abuse, Bethesda, MDGoogle Scholar
  70. 67.
    Kapadia G, Fayez M (1970) Peyote constituents: chemistry, biogenesis and biological effects. J Pharm Sci 59:1699–1727PubMedCrossRefGoogle Scholar
  71. 68.
    Katz M, Waskow I, Olsson J (1968) Characterizing the psychological state produced by LSD. J Abnorm Psychol 73(1):1–14PubMedCrossRefGoogle Scholar
  72. 69.
    Keeler MH (1967) Lysergic acid diethylamide: adverse reactions and use in experimental therapy. N C Med J 28(8):323–327PubMedGoogle Scholar
  73. 70.
    Klock J, Boerner U, Becker C (1973) Coma, hyperthermia and bleeding associated with massive LSD overdose. West J Med 20:183–188Google Scholar
  74. 71.
    Leikin J, Krantz A, Zell-Kanter M et al (1989) Clinical features and management of intoxication due to hallucinogenic drugs. Med Toxicol Adverse Drug Exp 4(5):324–350PubMedCrossRefGoogle Scholar
  75. 72.
    Leonardi ET, Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10:231–238PubMedGoogle Scholar
  76. 73.
    Lerner A, Gelkopf M, Oyffe I et al (2000) LSD-induced hallucinogen persisting perception disorder treatment with clonidine: an open pilot study. Int Clin Psychopharacol 8:35–37CrossRefGoogle Scholar
  77. 74.
    Lerner A, Gelkopf M, Skladman I et al (2002) Flashback and hallucinogen persisting perception disorder: clinical aspects and pharmacological treatment approach. Isr J Psychiatry Related Sci 39:92–99Google Scholar
  78. 75.
    Lerner A, Gelkopf M, Skladman I et al (2003) Clonazepam treatment of lysergic acid diethylamide-induced hallucinogen persisting perception disorder with anxiety features. Int Clin Psychopharmacol 18:101–105PubMedCrossRefGoogle Scholar
  79. 76.
    Lerner A, Oyffe I, Isaacs G et al (1997) Naltrexone treatment of hallucinogen persisting perception disorder. Am J Psychiatry 154(8):154–437Google Scholar
  80. 77.
    Lindenblatt H, Kraemer E, Holzmann-Erens P et al (1998) Quantitation of psilocin in human plasma by high-performance liquid chromatography and electrochemical detection: comparison of liquid-liquid extraction with automated on-line solid-phase extraction. J Chromatogr Biomed Sci Appl 709:255–263CrossRefGoogle Scholar
  81. 78.
    Linton H, Langs R (1962) Subjective reactions to lysergic acid diethylamide (LSD-25). Arch Gen Psychiatry 6:352–368CrossRefGoogle Scholar
  82. 79.
    Lisansky J, Strassman R, Janowsky D et al (1984) Transient psychosis: diagnosis, management and evaluation. Brunner/Mazel, New YorkGoogle Scholar
  83. 80.
    Mack R (1986) Marching to a different cactus; peyote (mescaline) intoxication. N C Med J 47:137–138PubMedGoogle Scholar
  84. 81.
    Malleson N (1971) Acute adverse reactions to LSD in clinical and experimental use in the United Kingdom. Br J Psychiatry 118:229–230PubMedCrossRefGoogle Scholar
  85. 82.
    Markel H, Lee A, Holmes RD et al (1994) LSD flashback syndrome exacerbated by selective serotonin reuptake inhibitor antidepressants in adolescents. J Pediatr 125:817–819PubMedCrossRefGoogle Scholar
  86. 83.
    Maxwell D, Polkey M, Henry J (1993) Hyponatraemia and catatonic stupor after taking ‘ecstasy.’ Br Med J 307:1399CrossRefGoogle Scholar
  87. 84.
    Mazur S, Hitchcock T (2001) Spontaneous pneumomediastinum, pneumothorax and Ecstasy abuse. Emerg Med 13:121–123CrossRefGoogle Scholar
  88. 85.
    McCann UD, Ricaurte GA (1992) MDMA (‘Ecstasy’) and panic disorder: induction by a single dose. Biol Psychiatry 32:950–953PubMedCrossRefGoogle Scholar
  89. 86.
    McGee R (1984) Flashbacks and memory phenomena: a comment on Flashback phenomena—clinical and diagnostic dilemmas. J Nerv Ment Dis 172(5):273–278PubMedCrossRefGoogle Scholar
  90. 87.
    Miller NS (1997) The principles and practice of addictions in psychiatry. W.B Saunders Company, Philadelphia, USAGoogle Scholar
  91. 88.
    Milroy C, Clark J, Forrest A (1996) Pathology of deaths associated with “ecstasy” and “eve” misuse. J Clin Pathol 49:149–153PubMedCrossRefGoogle Scholar
  92. 89.
    Moore K, Mozayani A, Fierro M et al (1992) Distribution of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) stereoisomers in a fatal poisoning. Forensic Sci Int 83:111–119CrossRefGoogle Scholar
  93. 90.
    Morehead D (1997) Exacerbation of hallucinogen persisting perception disorder with risperidone. J Clin Psychopharmacol 17:327–328PubMedCrossRefGoogle Scholar
  94. 91.
    Morland J (2000) Toxicity of drug abuse-amphetamine designer drugs (ecstasy): mental effects and consequences of single dose use. Toxicol Lett 112–113:147–152PubMedCrossRefGoogle Scholar
  95. 92.
    Morton J (2005) Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol 5:79–86PubMedCrossRefGoogle Scholar
  96. 93.
    Moskowitz D (1971) Use of haloperidol to reduce LSD flashback. Arch Gen Psychiatry 40:884–889Google Scholar
  97. 94.
    Mulvey E (2008) Nine arrested for violation of combat meth act. Accessed on 18 Aug 2008
  98. 95.
    National Drug Intelligence Center (2003) LSD fast facts. Accessed 15 Aug 2008
  99. 96.
    National Drug Intelligence Center (2006) National drug threat assessment 2006. Report No. 2006-Q0317–001. Author, Johnstown, PA. Available at Accessed 30 Jun 2010
  100. 97.
    National Institute on Drug Abuse (2001) Research report: hallucinogens and dissociative drugsGoogle Scholar
  101. 98.
    National Institute on Drug Abuse (2002) The monitoring the future national results on adolescent drug use: overview of key findings. University of Michigan Institute for Social Research, Ann Arbor, MIGoogle Scholar
  102. 99.
    National Institute on Drug Abuse (2006, June [printed November 2006]) Community Epidemiology Work Group: epidemiologic trends in drug abuse advance report. NIH Publication No. 06–5878A. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD. Available as a PDF at Accessed 30 Jun 2010
  103. 100.
    Nichols D (1986) Differences between the mechanisms of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens. J Psychoactive Drugs 18:305–313PubMedCrossRefGoogle Scholar
  104. 101.
    Oesterheld J, Armstrong S, Cozza K (2004) Ecstasy: pharmacodynamic and pharmacokinetic interactions. Psychosomatics 45:84–87PubMedCrossRefGoogle Scholar
  105. 102.
    Office of Applied Studies (2006) Results from the 2005 national survey on drug use and health: national findings. DHHS Publication No. SMA 06–4194, NSDUH Series H-30. Substance Abuse and Mental Health Services Administration, Rockville, MDGoogle Scholar
  106. 103.
    Olson K (2004) Poisoning & drug overdose. Lang Medical Books/McGraw-Hill, New YorkGoogle Scholar
  107. 104.
    Pallanti S, Mazzi D (1992) MDMA (Ecstasy) precipitation of panic disorder. Biol Psychiatry 32:91–95PubMedCrossRefGoogle Scholar
  108. 105.
    Papac DI, Foltz RL (1990) Measurement of lysergic acid diethylamide (LSD) in human plasma by gas chromatography/negative ion chemical ionization mass spectrometry. J Anal Toxicol 14(3):189–190PubMedGoogle Scholar
  109. 106.
    Parrott AC, Buchanan T, Scholey AB et al (2002) Ecstasy/MDMA attributed problems reported by novice, moderateandheavy recreational users. Hum Psychopharmacol 17:309–312PubMedCrossRefGoogle Scholar
  110. 107.
    Partilla J, Dersch C, Yu H et al (2000) Neurochemical neutralization of amphetamine-type stimulants in rat brain by the indatraline analog (–)-HY038. Brain Res Bull 53:821–826PubMedCrossRefGoogle Scholar
  111. 108.
    Passie T, Seifert J, Schneider U et al (2002) The pharmacology of psilocybin. Addict Biol 7:357–364PubMedCrossRefGoogle Scholar
  112. 109.
    Peroutka J, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1:273–277PubMedGoogle Scholar
  113. 110.
    Quinn G, McCarthy G, Harries D (1999) Spontaneous pneumomediastinum and Ecstasy abuse. J Accid Emerg Med 16:382CrossRefGoogle Scholar
  114. 111.
    Rejali D, Glen P, Odom N (2002) Pneumomediastinum following Ecstasy (methylenedioxymethamphetamine, MDMA) ingestion in two people at the same ‘rave’. J Laryngol Otol 116:75–76PubMedCrossRefGoogle Scholar
  115. 112.
    Renkel M (1957) Pharmacodynamics of LSD and mescaline. J Nerve Ment Dis 125:424–427CrossRefGoogle Scholar
  116. 113.
    Rohrig T, Prouty R (1992) Tissue distribution of methylenedioxymethamphetamine. J Anal Toxicol 16:52–53PubMedGoogle Scholar
  117. 114.
    Rothwell P, Grant R (1993) Cerebral venous sinus thrombosis induced by ecstasy. J Neurol Neuosurg Psychiatry 56:1035CrossRefGoogle Scholar
  118. 115.
    Sandison RA, Spencer AM, Whitelaw JDA (1954) The therapeutic value of lysergic acid diethylamide in mental illness. J Ment Sci 100:149Google Scholar
  119. 116.
    Schick J, Smith D (1970) Analysis of the LSD flashback. J Psychedelic Drugs 3:13–19CrossRefGoogle Scholar
  120. 117.
    Schiff PL (2006) Ergot and its alkaloids. Am J Pharm Educ 70(5):98PubMedCrossRefGoogle Scholar
  121. 118.
    Schmidt C (1987) Acute administration of methylenedioxymethamphetamine: comparison with the neurochemical effects of its N-desmethyl and N-ethyl analogs. Eur J Pharmacol 136:81–88PubMedCrossRefGoogle Scholar
  122. 119.
    Schwartz C (1967) Paradoxical responses to chlorpromazine after LSD. Psychosomatics 8:210–211Google Scholar
  123. 120.
    Schwartz R (1988) Mescaline: a survey. Am Fam Physician 37:122–124PubMedGoogle Scholar
  124. 121.
    Schwartz R, Comerci G, Meeks JE (1987) LSD: patterns of use by chemically dependent adolescents. J Pediatr 111:936–938PubMedCrossRefGoogle Scholar
  125. 122.
    Schwartz R, Miller N (1997) MDMA (Ecstasy) and the rave: a review. Pediatrics 100:705–708PubMedCrossRefGoogle Scholar
  126. 123.
    Shulgin A, Shulgin A (1997) Tihkal: The Continuation, BerkeleyGoogle Scholar
  127. 124.
    Smith K, Larive L, Romanelli F (2002) Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 59:1067–1076PubMedGoogle Scholar
  128. 125.
    Solursh L (1976) Emergency treatment of acute adverse reactions to hallucinogenic drugs. Acute drug emergencies. Academic, New YorkGoogle Scholar
  129. 126.
    Solursh L(1968) Use of diazepam in hallucinogenic drug crises. JAMA 205:644–645PubMedCrossRefGoogle Scholar
  130. 127.
    Stahl S (1996) Essential psychopharmacology, neuroscientific basis and practical applications. University Press, Cambridge, UKGoogle Scholar
  131. 128.
    Stamets P (1996) Psilocybin mushrooms of the world: an identification guide. Ten Speed, Berkeley, CAGoogle Scholar
  132. 129.
    Strassman R (1984) Adverse reactions to psychedelic drugs: a review of the literature. J Nerv Ment Dis 172(10):577–595PubMedCrossRefGoogle Scholar
  133. 130.
    Suarez R, Riemersma R (1988) “Ecstasy” and sudden cardiac death. Am J Forensic Med Pathol 9:339–341PubMedCrossRefGoogle Scholar
  134. 131.
    Substance Abuse and Mental Health Services Administration, Office of Applied Studies (July 5, 2007) The NSDUH report: patterns of hallucinogen use and initiation: 2004 and 2005. Rockville, MDGoogle Scholar
  135. 132.
    Thompson M, Callaghan P, Hunt G et al (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience 146(2):509–514PubMedCrossRefGoogle Scholar
  136. 133.
    Thurlow HJ, Girvin JP (1971) Use of antiepileptic medication in treating flashbacks from hallucinogenic drugs. Can Med Assoc 105:947–948Google Scholar
  137. 134.
    Ungerleider J Frank I (1976) Acute drug Emergencies. Academic, New YorkGoogle Scholar
  138. 135.
    Ungerleider J, DeAngelis G (1981) Substance abuse-Clinical Problems and Perspectives. Williams & Wilkins, Baltimore, MDGoogle Scholar
  139. 136.
    Uys J, Niesink R (2005) Pharmacological aspects of the combined use of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and gamma-hydroxybutyric acid (GHB): a review of the literature. Drug Alcohol Rev 24:359–368PubMedCrossRefGoogle Scholar
  140. 137.
    Velea D, Hautefeuille M, Vazeille G et al (1999) Nouvelles drogues synthetiques empathogenes [New synthesis empathogenic agents]. Encephale 25:508–514PubMedGoogle Scholar
  141. 138.
    Verebey K, Alrazi J, Jaffe J (1988) The complications of ‘ecstasy’ (MDMA). JAMA 259(11):1649–1650PubMedCrossRefGoogle Scholar
  142. 139.
    Vollenweider F, Gamma A, Liechti M et al (1998) Psychological and cardiovascular effects and short term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacolgoy 19:241–251Google Scholar
  143. 140.
    Wasson G (1971) Soma of the Aryans: an ancient hallucinogen? J Psychedelic Drugs 3(2):40–46CrossRefGoogle Scholar
  144. 141.
    Wesson D, Smith D (1984) An analysis of psychedelic drug flashbacks. Am J Drug Alcohol Abuse 3:425–438CrossRefGoogle Scholar
  145. 142.
    West L, Pierce C, Thomas W (1962) Lysergic acid diethylamid: its effect on a male asiatic elephant. Science 138:1100–1103PubMedCrossRefGoogle Scholar
  146. 143.
    Winter JC (1971) Tolerance to a behavioral effect of lysergic acid diethylamide and cross-tolerance to mescaline in the rat: absence of a metabolic component. J Pharmacol Exp Ther 178(3):625–630PubMedGoogle Scholar
  147. 144.
    Winter JC (2009) Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines. Psychopharmacology (Berl) 203(2):251–263. Epub 2008 Nov 1Google Scholar
  148. 145.
    Wolbach AB Jr, Isbell H, Miner EJ (1962) Cross tolerance between mescaline and LSD-25, with a comparison of the mescaline and LSD reactions. Psychopharmacologia 12(3):1–14CrossRefGoogle Scholar
  149. 146.
    Wolff K, Hay A, Sherlock K et al (1995) Contents of ‘ecstasy’. Lancet 346:1100–1101PubMedCrossRefGoogle Scholar
  150. 147.
    Young C (1997) Sertraline treatment of hallucinogen persisting perception disorder. J Clin Psychiatry 58:85PubMedCrossRefGoogle Scholar
  151. 148.
    Ziporyn T (1986) A growing industry and menace: makeshift laboratory’s designer drugs. J Am Med Assoc 256:3061–3063CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Department of Psychiatry, Neuroscience CenterLehigh Valley Health NetworkAllentownUSA

Personalised recommendations